The widening loss and accelerating cash burn are concerning for a pre-revenue biotech, but the $215.9M cash runway through 2028 and upcoming Phase 3 catalyst for givastomig provide a binary event timeline. Traders should watch for the ESMO poster presentation on Oct 25, 2026 and any FDA feedback on the accelerated approval pathway before YE 2026.
Price Chart
Executive Summary
NovaBridge Biosciences reported H1 2026 net loss of $37.9M ($0.14 per share), widening from $8.7M ($0.05) a year ago, as R&D spending tripled to $14.3M and administrative costs surged to $26.4M. The company ended June with $215.9M in cash, sufficient to fund givastomig's Phase 3 interim data readout in 2028. Key catalysts include potential Phase 3 initiation for givastomig under an accelerated approval pathway by YE 2026 and Phase 2b start for VIS-101 in H2 2026.
Key Financial Metrics
Key Facts
- Net loss widened to $37.9M for H1 2026 vs $8.7M in H1 2025
- R&D expenses tripled to $14.3M from $4.1M, driven by givastomig clinical development
- Administrative expenses surged to $26.4M from $8.3M, including $3.8M write-off of deferred offering costs
- Cash position of $215.9M provides runway through givastomig Phase 3 interim data in 2028
- Givastomig received FDA Fast Track Designation in June 2026 for 1L HER2-negative GEA
- Phase 3 registrational study for givastomig could initiate as early as YE 2026 under Accelerated Approval Pathway
- VIS-101 Phase 2b program in nAMD expected to start H2 2026
Financial Impact
Net loss increased $29.2M YoY; cash burn from operations was $32.9M in H1 2026 vs $7.8M in H1 2025
Risk Factors
- Cash burn rate tripled YoY; at current pace, runway may be shorter than projected
- Givastomig Phase 3 may not meet endpoints or receive accelerated approval
- VIS-101 Phase 2b results could disappoint, impairing ophthalmology franchise value
- No revenue stream; fully dependent on pipeline success and capital markets access
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3348212 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 25, 2026 2d ago | Press Release | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 23, 2026 4d ago | 6-K | $1.37 | awaiting T+5 | — | $1.25 (−8.39%) |
Oct 13, 2026 14d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.25 (−2.71%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.25 (−34.29%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.25 (−29.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers